Avacta Group Plc
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christina Marie Coughlin
- Full Time Employees
- 154
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Thorp Arch Estate Wetherby United Kingdom LS23 7FA
- IPO Date
- May 22, 2020
- Website
- avacta.com
- Similar Companies
- Business
- Avacta Group plc is a clinical-stage United Kingdom-based life sciences company that develops peptide drug conjugates utilizing its proprietary pre|CISION platform, which employs a tumor-specific fibroblast activation protein substrate to release active anti-tumor payloads selectively in solid tumor microenvironments; its lead candidate AVA6000 (FAP-Dox or faridoxorubicin) is a pre|CISION-enabled doxorubicin conjugate advancing in Phase 1b trials for salivary gland cancer, triple negative breast cancer, and high-grade soft tissue sarcoma, while AVA6103 (FAP-EXd) is a pre|CISION-enabled exatecan conjugate in IND-enabling studies targeting Phase 1 initiation in early 2026; the pipeline further includes early-stage biologic drug conjugates and a dual payload technology (AVA6207). The company, founded in 2003 and headquartered at Scale Space White City Imperial College Campus in London, operates primarily in the oncology therapeutics segment with revenue historically derived from South Korea and international markets following the divestment of its non-core diagnostics business, including Launch Diagnostics and Coris Holdings, in 2025 to focus exclusively on pre|CISION-based oncology assets. Recent developments include a strategic AI collaboration with Tempus to optimize patient populations and trial design, an oversubscribed £16 million equity fundraise in October 2025 extending cash runway into H2 2026 while amending Heights Capital convertible bond terms with deferred repayments and a reset conversion price of 75 pence, strengthened executive leadership with new Chief Financial Officer Brian Hahn, Chief Scientific Officer Michelle Morrow, and non-executive directors David Bryant and Richard Hughes, and presentation of Phase 1a AVA6000 data at ESMO 2025 showing 91% disease control rate.
Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026
Avacta Group Plc (AVCTF) Q4 2025 Earnings Call Transcript
Unaudited Preliminary Results for the Year Ended December 31, 2025
Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026
Avacta Group (OTCMKTS:AVCTF) Stock Price Down 5.3% – Here’s What Happened
Avacta Group Plc (AVCTF) Discusses Initial Faridoxorubicin Phase Ib Data and Safety Profile in Salivary Gland Cancer Transcript
Avacta Group (OTCMKTS:AVCTF) Trading 1.2% Higher – What’s Next?
Short Interest in Avacta Group Plc (OTCMKTS:AVCTF) Rises By 61.6%
Avacta Group Plc (AVCTF) Q2 2025 Earnings Call Transcript
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development
Avacta Group Plc (AVCTF) Preliminary Q4 2024 Earnings Conference Call Transcript
Avacta Group Plc (AVCTF) Q2 2024 Earnings Call Transcript
Avacta Group PLC (AVCTF) Q4 2023 Earnings Call Transcript